Literature DB >> 9549648

Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures.

G M Kochak1, J G Page, R A Buchanan, R Peters, C S Padgett.   

Abstract

A 56-day pharmacokinetic study of zonisamide was conducted in 24 healthy volunteers. Steady state was achieved in 29 days including two dose escalations, and in an average of 15 days from the last dose adjustment. Twice-daily administration of 200 mg every 12 hours produced a 14% serum level fluctuation at steady state. After once-daily administration of 400 mg, a 27% serum level fluctuation was observed. The terminal-phase half-life after the last dose was 63 to 69 hours, which is consistent with the half-life of 52 to 60 hours found in single-dose studies. This result demonstrates that zonisamide is not an autoinducer. Serum oral clearance of 0.60 to 0.71 L/hr (0.121-0.132 mL/min/kg) was similar to that observed in other multiple-dose studies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9549648     DOI: 10.1002/j.1552-4604.1998.tb04406.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  9 in total

1.  Treating epilepsy in the setting of medical comorbidities.

Authors:  Nivedita U Jerath; Dronacharya Lamichhane; Madhu Jasti; Vinusha Yarlagadda; Eduardo Zilli; Yara Nazzal; Mark Granner
Journal:  Curr Treat Options Neurol       Date:  2014-07       Impact factor: 3.598

Review 2.  Treating epilepsy in the elderly: safety considerations.

Authors:  S Arroyo; G Kramer
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

3.  Selection of antiepileptic drugs in older people.

Authors:  Batool F Kirmani; Diana Mungall Robinson; Adeline Kikam; Ekokobe Fonkem; Daniel Cruz
Journal:  Curr Treat Options Neurol       Date:  2014-06       Impact factor: 3.972

Review 4.  Use of second-generation antiepileptic drugs in the pediatric population.

Authors:  Allison M Chung; Lea S Eiland
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

5.  Pharmacometabolomics applied to zonisamide pharmacokinetic parameter prediction.

Authors:  J C Martínez-Ávila; A García Bartolomé; I García; I Dapía; Hoi Y Tong; L Díaz; P Guerra; J Frías; A J Carcás Sansuan; A M Borobia
Journal:  Metabolomics       Date:  2018-05-09       Impact factor: 4.290

Review 6.  Drug interactions with the newer antiepileptic drugs (AEDs)--part 1: pharmacokinetic and pharmacodynamic interactions between AEDs.

Authors:  Philip N Patsalos
Journal:  Clin Pharmacokinet       Date:  2013-11       Impact factor: 6.447

Review 7.  Update on once-daily zonisamide monotherapy in partial seizures.

Authors:  Pegah Afra; Bola Adamolekun
Journal:  Neuropsychiatr Dis Treat       Date:  2014-03-19       Impact factor: 2.570

8.  Zonisamide - a review of experience and use in partial seizures.

Authors:  Angus A Wilfong; L James Willmore
Journal:  Neuropsychiatr Dis Treat       Date:  2006-09       Impact factor: 2.570

Review 9.  Profile of once-daily zonisamide as monotherapy for treatment of partial seizures in adults.

Authors:  Marco Mula
Journal:  Drug Des Devel Ther       Date:  2013-05-14       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.